Dyne Therapeutics (NASDAQ:DYN) Director Acquires $42,800.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner acquired 2,500 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $17.12 per share, with a total value of $42,800.00. Following the completion of the transaction, the director owned 18,000 shares in the company, valued at $308,160. This represents a 16.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Dyne Therapeutics Price Performance

DYN stock remained flat at $17.37 during trading on Friday. 1,448,061 shares of the company were exchanged, compared to its average volume of 2,008,177. The business’s fifty day moving average is $18.33 and its 200-day moving average is $18.40. The company has a market capitalization of $2.87 billion, a P/E ratio of -5.39 and a beta of 1.08. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the firm earned ($1.05) EPS. On average, analysts forecast that Dyne Therapeutics, Inc. will post -2.99 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of the company. Creative Planning lifted its stake in shares of Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after buying an additional 1,109 shares in the last quarter. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics in the first quarter valued at $26,000. Caxton Associates LLP lifted its stake in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Dyne Therapeutics by 9.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after buying an additional 2,108 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DYN has been the subject of several recent research reports. Morgan Stanley decreased their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 15th. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $35.00.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.